FDA feedback provides clarity on trial protocol and primary endpoint that could support a potential Phase 3 study of the ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare ...
Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first ...
Session: Advances in Oncology Panel Presenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin Date/time: ...
Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting ...
Poster presentation to feature data highlighting Kalohexis' novel approach to melanocortin agonism and its oral MC3R/MC4R ...
Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M. Fitzgerald to executive vice president ...
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded ...
European Commission-funded MINIGRAPH project integrates graphene neural interfaces, implantable electronics with robotic ...
(“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and ...
The Taiwan FDA approved the amended protocol and the lead Taiwan site received IRB approval during September of 2026. The ...
MimiVax Inc., a clinical-stage biotechnology company dedicated to the development of innovative cancer immunotherapies, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results